Aflac AFL Cancer — Weighted-average interest, current discount rate
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Aflac in its filing.
Tagged under the XBRL concept us-gaap:LiabilityForFuturePolicyBenefitCurrentWeightedAverageDiscountRate.
The official record: Aflac’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Aflac's cancer — weighted-average interest, current discount rate.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI

Claude
Questions, answered.
- What is Aflac's cancer — weighted-average interest, current discount rate?
- Aflac (AFL) reported cancer — weighted-average interest, current discount rate of 3.8% in Q1 2026.
- How has Aflac's cancer — weighted-average interest, current discount rate changed year-over-year?
- Aflac's cancer — weighted-average interest, current discount rate increased by 40.7% year-over-year, from 2.7% to 3.8%.
- What is the long-term trend for Aflac's cancer — weighted-average interest, current discount rate?
- Over 2 years (2023 to 2025), Aflac's cancer — weighted-average interest, current discount rate has grown at a 29.1% compound annual growth rate (CAGR), from 6.9% to 11.5%.
- What does cancer — weighted-average interest, current discount rate mean?
- This represents the current market-based interest rate used to discount future policy benefit liabilities for the cancer insurance segment. It reflects the impact of current economic conditions on the valuation of long-term insurance obligations. Changes in this rate directly influence the balance sheet valuation of reserves.